Thoracic Oncology at Robert H. Lurie Comprehensive Cancer Center (Northwestern Memorial Hospital)
Welcome,         Profile    Billing    Logout  
 13 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chae, Young
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
LUNG-MAP SUB-STUDY, NCT06031688: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Recruiting
2
56
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, Tepotinib, c-Met Inhibitor MSC2156119J, EMD 1214063, EMD-1214063, EMD1214063, MSC2156119J
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, EMD Serono
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
05/28
05/29
EDO-S101-1002, NCT03345485 / 2020-004246-11: Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

Completed
1/2
71
Europe, Canada, US
Tinostamustine 60mg/m2 over 30min, EDO-S101, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, EDO-S101., Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Mundipharma Research Limited, Mundipharma Research Limited
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
07/22
03/23
NCT03061188: Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

Completed
1
15
US
Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pharmacological Study, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
Northwestern University, Bristol-Myers Squibb, AbbVie, National Cancer Institute (NCI)
Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm, Refractory Mantle Cell Lymphoma, T-Cell Non-Hodgkin Lymphoma, Unresectable Solid Neoplasm
03/18
08/20
Tomic, Rade
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Terminated
2
153
Europe, Canada, Japan, US, RoW
HZN-825, Placebo
Amgen
Idiopathic Pulmonary Fibrosis
07/24
01/25
NCT05571059: Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2
128
US
Ifetroban Sodium, ifetroban, Placebo
Cumberland Pharmaceuticals
Idiopathic Pulmonary Fibrosis
01/26
01/26
Bharat, Ankit
No trials found
Chung, Liam Il-Young
No trials found

Download Options